国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Technology

Chinese researchers publish major clinical study on ovarian cancer

By Li Jing | chinadaily.com.cn | Updated: 2025-12-15 17:37
Share
Share - WeChat

A major Chinese clinical study on ovarian cancer has been published in CA: A Cancer Journal for Clinicians, one of the world's highest-impact medical journal, marking a first for a Chinese researcher-led gynecological cancer trial, researchers said in Beijing on Sunday.

The phase III FZOCUS-1 study tested fluzoparib, a PARP inhibitor developed by Chinese pharmaceutical giant Hengrui Pharma. The trial evaluated the drug as a "maintenance" therapy, treatment given to prevent cancer recurrence after initial chemotherapy for advanced ovarian cancer, either alone or in combination with the targeted drug apatinib.

Conducted over six years at 54 hospitals across China, the randomized, double-blind trial enrolled 674 patients. Results showed that fluzoparib-based maintenance therapy significantly delayed disease progression compared with a placebo.

In the overall study population, patients receiving fluzoparib alone achieved a median progression-free survival of 29.9 months, the research team said.

The results were even more striking for patients with BRCA mutations. In this group, median progression-free survival reached 47.8 months, nearly three times that of the placebo group.

The study also found that patients with a specific generic marker of homologous recombination deficiency could benefit from fluzoparib alone, potentially allowing them to avoid the side effects and extra costs associated with combination therapy. Meanwhile, patients without this generic marker, who typically face poorer outcomes, showed encouraging results from the combination therapy of fluzoparib and apatinib.

"Ovarian cancer is often diagnosed late and remains difficult to treat," Wu Lingying, the study's principal investigator from the Cancer Hospital of the Chinese Academy of Medical Sciences, said.

"This research, designed and completed entirely by Chinese teams, provides solid evidence that can help improve treatment decisions both in China and globally."

Ovarian cancer causes about 200,000 deaths worldwide each year. In China, around 61,000 women are diagnosed annually, with roughly 38,000 deaths, according to the research team.

Wang Quanren, vice-president of Hengrui Pharma, said the high-profile publication highlights the growing impact of China's drug innovation. He added that fluzoparib has been included in China's national medical insurance program since 2021, making the treatment more accessible to patients.

Researchers said the findings offer new, practical guidance for precision treatment of advanced ovarian cancer and underscore China's expanding role in global clinical research.

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
长沙县| 瓦房店市| 玉山县| 南漳县| 青阳县| 五寨县| 双江| 永登县| 洪雅县| 安阳市| 余姚市| 巍山| 石阡县| 石台县| 天镇县| 黔西县| 曲阜市| 西丰县| 吴堡县| 泗阳县| 姚安县| 涟水县| 独山县| 勃利县| 苍溪县| 赞皇县| 武汉市| 蓝田县| 靖宇县| 长宁县| 清苑县| 建宁县| 惠水县| 元江| 宁海县| 丰顺县| 霍城县| 交口县| 齐河县| 梓潼县| 阿瓦提县|